Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 11/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.55 |
| ▸ | TSHR | P16473 | 5/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14775621 | 0.98 | EGFR (0.66) | EGFRCYP1A2CYP3A4CLK4CYP2D6 | |
| Hydrochloric Acid SCHEMBL27318612 | 0.98 | EGFR (0.66) | EGFRCYP1A2CYP3A4CLK4CYP2D6 | |
| SCHEMBL21415554 | 0.81 | EGFR (0.60) | EGFRCYP1A2ALDH1A1CYP2C19CYP2C9 | |
| SCHEMBL3109912 | 0.81 | EGFR (1.00) | EGFR | |
| Hydrochloric Acid SCHEMBL6182107 | 0.80 | EGFR (0.97) | EGFR | |
| SCHEMBL28800673 | 0.79 | EGFR (0.58) | EGFRCLK4ALDH1A1LMNAPI4KA | |
| SCHEMBL27887833 | 0.79 | EGFR (0.57) | EGFRCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11013925 | 0.79 | HTT (0.61) | EGFRCYP1A2ALDH1A1CYP2C19CYP2C9 | |
| Hydrochloric Acid SCHEMBL8375173 | 0.77 | HTT (0.59) | EGFRALDH1A1MAPK1LMNAHSD17B10 | |
| SCHEMBL24851503 | 0.77 | CYP1A2 (0.59) | EGFRCYP1A2CYP3A4CLK4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104363908-A | Pyrrolidino heterocycles | HOFFMANN LA ROCHE | 2015-02-18 | — | — | CN | claimed |
| CN-118900838-A | Heterocyclic compounds, compositions thereof and methods of treatment thereof | 百济神州有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-118660880-A | Quinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| CN-117736207-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-115362003-B | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-117624063-A | Heterocyclic compound and application thereof | 中国科学院上海药物研究所 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023133217-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023121429-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | 아주대학교산학협력단 | 2023-06-29 | — | — | WO | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| CN-104693211-A | Imidazole derivative as antiviral agent and pharmaceutical application thereof | NANJING MINGDE NEW DRUG RES AND DEV CO LTD | 2015-06-10 | — | — | CN | disclosed |
| CN-104363908-A | Pyrrolidino heterocycles | HOFFMANN LA ROCHE | 2015-02-18 | — | — | CN | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| EP-2342191-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-07-13 | — | — | EP | disclosed |
| CN-101779124-A | modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC | 2010-07-14 | — | — | CN | disclosed |
| WO-2010030027-A1 | AROMATIC NITROGEN-CONTAINING 6-MEMBERED RING COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-03-18 | — | — | WO | disclosed |
| US-4510307-A | 6-Quinazolinesulfonyl derivatives and process for preparation thereof | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-04-09 | — | — | US | disclosed |
| EP-0046572-B1 | 6-QUINAZOLINESULFONYL DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-31 | — | — | EP | disclosed |
| EP-0046572-A2 | 6-Quinazolinesulfonyl derivatives and process for preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | EGFR 460/4885CYP1A2 3130/4885CYP3A4 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.